Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Nanotechnol. 2021 Nov;16(11):1180-1194. doi: 10.1038/s41565-021-01017-9. Epub 2021 Nov 10.
Nanoparticles are often engineered as a scaffolding system to combine targeting, imaging and/or therapeutic moieties into a unitary agent. However, mostly overlooked, the nanomaterial itself interacts with biological systems exclusive of application-specific particle functionalization. This nanoparticle biointerface has been found to elicit specific biological effects, which we term 'ancillary effects'. In this Review, we describe the current state of knowledge of nanobiology gleaned from existing studies of ancillary effects with the objectives to describe the potential of nanoparticles to modulate biological effects independently of any engineered function; evaluate how these effects might be relevant for nanomedicine design and functional considerations, particularly how they might be useful to inform clinical decision-making; identify potential clinical harm that arises from adverse nanoparticle interactions with biology; and, finally, highlight the current lack of knowledge in this area as both a barrier and an incentive to the further development of nanomedicine.
纳米粒子通常被设计为一种支架系统,将靶向、成像和/或治疗部分结合到一个单一的制剂中。然而,人们大多忽略了纳米材料本身与生物系统的相互作用,而这种相互作用与特定的粒子功能化无关。我们发现这种纳米颗粒生物界面会引起特定的生物学效应,我们称之为“辅助效应”。在这篇综述中,我们描述了从辅助效应的现有研究中获得的纳米生物学的现有知识状态,目的是描述纳米粒子在不依赖任何工程功能的情况下调节生物学效应的潜力;评估这些效应如何与纳米医学设计和功能考虑相关,特别是它们如何有助于为临床决策提供信息;确定由于纳米粒子与生物学的不良相互作用而产生的潜在临床危害;最后,强调该领域目前知识的缺乏既是纳米医学进一步发展的障碍,也是激励因素。